

## Supplementary material

**Supplementary Table 1** Treatment outcomes and adverse events of malignant etiology

	EUS-GE (n=196)	Enteral stenting (n=126)	Surgical- GE (n=43)	Overall P- value	P-value EUS- GE vs. enteral stenting ¶	P-value EUS- GE vs. surgical-GE ¶
Technical success (N, %)	192 (98.0)	125 (99.2)	43 (100.0)	0.82	0.65	1.00
Clinical success (N, %)	192 (98.0)	116 (92.1)	39 (90.7)	0.01*	0.01*	0.04
Length of hospital stay (days, median [IQR])	2 (1-3)	3 (1-9.25)	6 (3-9)	<0.0001	<0.0001*	<0.0001*
Rate of re-intervention (N, %)	1 (0.5)	14 (11.1)	5 (11.6)	<0.0001	<0.0001*	<0.0001*
Duration of follow-up (days, median [IQR])	202 (86.75- 370.5)	56 (22.75- 208)	154 (43- 477)	<0.0001	<0.0001*	0.67
AEs, N (%)	18 (9.2)	50 (39.7)	12 (27.9)	< 0.0001	< 0.0001*	< 0.0001*

P-value of less than 0.0167 indicates statistical significance based on a Bonferroni correction and \* indicates statistical significance. **Abbreviations:** AE: adverse event; ES: enteral stenting; EUS-GE: endoscopic ultrasound-guided gastroenterostomy; surgical-GE: surgical gastroenterostomy